|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 114.87 AUD | -2.36% |
|
+6.28% | -33.47% |
| 05:48pm | European Regulator Calls for Amgen's Tavneos to Have Authorization Revoked | DJ |
| 06-25 | US prices for new drugs fell in 2025 as fewer costly gene therapies were launched | RE |
Company Valuation: CSL Limited
Data adjusted to current consolidation scope
| Fiscal Period: June | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 97,314 | 89,299 | 89,052 | 95,184 | 76,024 | 37,984 | - | - |
| Change | - | -8.24% | -0.28% | 6.89% | -20.13% | -50.04% | - | - |
| Enterprise Value (EV) 1 | 101,307 | 88,520 | 99,731 | 105,710 | 85,005 | 46,832 | 46,054 | 45,394 |
| Change | - | -12.62% | 12.66% | 5.99% | -19.59% | -44.91% | -1.66% | -1.43% |
| P/E | 41x | 38.6x | 40.8x | 36.1x | 25.4x | -51.1x | 26.3x | 12.2x |
| PBR | 11.6x | 6.13x | 5.64x | 5.48x | 3.93x | 2.33x | 2.32x | 2.11x |
| PEG | - | -4.91x | -7.25x | 1.8x | 1.9x | 0x | -0x | 0x |
| Capitalization / Revenue | 9.44x | 8.45x | 6.69x | 6.43x | 4.89x | 2.47x | 2.42x | 2.33x |
| EV / Revenue | 9.83x | 8.38x | 7.49x | 7.14x | 5.46x | 3.04x | 2.94x | 2.79x |
| EV / EBITDA | 27.2x | 24.6x | 25.6x | 22.3x | 16.5x | 8.99x | 8.87x | 8.33x |
| EV / EBIT | 32.4x | 30.2x | 32.5x | 27.7x | 19x | 10.5x | 10.3x | 9.72x |
| EV / FCF | 41.8x | 57.1x | 72.6x | 55.2x | 29.1x | 16.6x | 15.3x | 15.6x |
| FCF Yield | 2.39% | 1.75% | 1.38% | 1.81% | 3.44% | 6.01% | 6.53% | 6.4% |
| Dividend per Share 2 | 2.22 | 2.22 | 2.36 | 2.64 | 2.92 | 2.85 | 2.935 | 3.1 |
| Rate of return | 1.04% | 1.2% | 1.28% | 1.34% | 1.86% | 3.59% | 3.7% | 3.91% |
| EPS 2 | 5.21 | 4.8 | 4.53 | 5.45 | 6.17 | -1.553 | 3.012 | 6.517 |
| Distribution rate | 42.6% | 46.3% | 52.1% | 48.4% | 47.3% | -184% | 97.4% | 47.6% |
| Net sales 1 | 10,310 | 10,562 | 13,310 | 14,800 | 15,558 | 15,387 | 15,669 | 16,278 |
| EBITDA 1 | 3,720 | 3,596 | 3,900 | 4,750 | 5,151 | 5,208 | 5,190 | 5,447 |
| EBIT 1 | 3,130 | 2,927 | 3,069 | 3,812 | 4,468 | 4,464 | 4,463 | 4,672 |
| Net income 1 | 2,375 | 2,255 | 2,194 | 2,642 | 3,002 | -893.4 | 1,187 | 3,114 |
| Net Debt 1 | 3,993 | -778.6 | 10,679 | 10,526 | 8,981 | 8,847 | 8,070 | 7,410 |
| Reference price 2 | 213.82 | 185.38 | 184.61 | 196.96 | 157.01 | 79.31 | 79.31 | 79.31 |
| Nbr of stocks (in thousands) | 455,126 | 481,706 | 482,372 | 483,253 | 484,212 | 478,912 | - | - |
| Announcement Date | 8/17/21 A | 8/16/22 A | 8/14/23 A | 8/12/24 A | 8/18/25 A | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -52.41x | 3.11x | 9.18x | 3.5% | 38.98B | |
| 16.06x | 3.47x | 9.38x | 0.63% | 63.09B | |
| 27.6x | 5.6x | 16.38x | 0.57% | 55.61B | |
| 34.26x | 11.6x | 21.89x | -.--% | 41.64B | |
| 32.61x | 3.5x | 10.75x | -.--% | 29.82B | |
| -6.91x | 9.65x | -5.88x | -.--% | 23.71B | |
| 16.02x | 2.93x | 9.07x | -.--% | 21.48B | |
| 47.92x | 5.23x | 36.25x | -.--% | 16.87B | |
| 25.96x | 5.39x | 14.51x | -.--% | 16.74B | |
| -32.03x | 14.93x | -45.4x | -.--% | 13.65B | |
| Average | 10.91x | 6.54x | 7.61x | 0.47% | 32.16B | |
| Weighted average by Cap. | 12.09x | 5.95x | 10.52x | 0.65% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CSL Stock
- Valuation CSL Limited
Select your edition
All financial news and data tailored to specific country editions
